Drug intelligence / Profile preview

C1K

Development stage: Phase 1
Lead developer: Ensol Biosciences
Modality: Small Molecules

Overview

C1K is a combination anticancer therapy developed by Ensol Biosciences. It is designed to overcome resistance to existing combination anticancer drugs and works by activating immune cells, thereby increasing tumor cell death. The specific components of the combination and detailed mechanism of action are not disclosed in public sources, but its primary function is as an immunomodulatory and cytotoxic agent for cancer treatment[1].

Other names: Charis 1000Charis1000Charis-1000

Beyond the preview

Go deeper on C1K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C1K.

Explore the full profile